cagrilintide/semaglutide Semaglutide + Cagrilintide Blend (Research) Cagrilintide / Semaglutide Blend (5mg

HbA1c improved by up to 2.2% in participants with type 2 diabetes

During a medically supervised GLP-1 program, the medication is only one part of the plan

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

Regulatory effect of intracellular polysaccharides from Antrodia cinnamomea on the intestinal microbiota of mice with antibiotic-associated diarrhea

When to Resume Treatment or Consider Alternatives If weight regain exceeds ten to fifteen pounds within four to six weeks of stopping, or if metabolic control deteriorates, resuming GLP-1 therapy may be clinically appropriate

Cumulative evidence shows that GLP-1 exerts direct and beneficial effects on hepatocytes to protect against the progression of NAFL to NASH, suggesting that GLP-1 could be a novel therapy for NASH 14,15,16,17